Steve Kanner

CSO Caribou Biosciences

Steve is the Chief Scientific Officer of Caribou Biosciences responsible for the Company’s therapeutic discovery, research, and development activities. Before joining Caribou in 2017, Steve was most recently Vice President, Head of Biology, at Arrowhead Pharmaceuticals leading a department in discovery of RNAi therapeutics for oncology, genetic diseases, and other indications. Prior to Arrowhead Pharmaceuticals, he served in various positions of increasing responsibility in both oncology and inflammation drug discovery at Bristol-Myers Squibb, Agensys/Astellas, and Astex Pharmaceuticals. Steve has authored over 80 publications in both peer-reviewed journals and books, and is an inventor on numerous U.S. and foreign patents and patent applications. Steve earned his undergraduate degree in Genetics from the University of California, Berkeley, and his Ph.D. in Immunology and Microbiology from the University of Miami’s Miller School of Medicine. He did his post-doctoral fellowship at the University of Virginia.

January 26, 2021

12:00 PM Advancing Clinical Efficacy in the Solid Tumor Space

Take a look at the current landscape for novel gene editing technologies to enhance T cell function, including the role of collaboration and partnerships in developing new CAR T therapies for solid tumors and broader cancer indications.